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Summary
 
Sorted CD4
 
1
 
 and CD8
 
1
 
 T cells from the peripheral blood or bone marrow of donor C57BL/6
(H-2
 
b
 
) mice were tested for their capacity to induce graft-versus-host disease (GVHD) by in-
jecting the cells, along with stringently T cell–depleted donor marrow cells, into lethally irradi-
ated BALB/c (H-2
 
d
 
) host mice. The peripheral blood T cells were at least 30 times more po-
tent than the marrow T cells in inducing lethal GVHD. As NK1.1
 
1
 
 T cells represented 
 
,
 
1%
of all T cells in the blood and 
 
z
 
30% of T cells in the marrow, the capacity of sorted marrow
NK1.1
 
2
 
 CD4
 
1
 
 and CD8
 
1
 
 T cells to induce GVHD was tested. The latter cells had markedly
increased potency, and adding back marrow NK1.1
 
1
 
 T cells suppressed GVHD. The marrow
NK1.1
 
1
 
 T cells secreted high levels of both interferon 
 
g
 
 (IFN-
 
g
 
) and interleukin 4 (IL-4), and
the NK1.1
 
2
 
 T cells secreted high levels of IFN-
 
g
 
 with little IL-4. Marrow NK1.1
 
1
 
 T cells ob-
tained from IL-4
 
2
 
/
 
2
 
 rather than wild-type C57BL/6 donors not only failed to prevent GVHD
but actually increased its severity. Together, these results demonstrate that GVHD is recipro-
cally regulated by the NK1.1
 
2
 
 and NK1.1
 
1
 
 T cell subsets via their differential production of
cytokines.
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A
 
llogeneic GVHD is a major barrier to the widespread
use of bone marrow transplantation in clinical medi-
cine (1–4). Acute GVHD is mediated by donor T cells ex-
pressing 
 
a
 
/
 
b
 
1
 
 TCRs (
 
a
 
/
 
b
 
1
 
 T cells) that recognize mole-
cules of the MHC (referred to as the H-2 complex in mice)
and their associated peptides (5–7). The central role of do-
nor T cells has been documented by the markedly reduced
frequency and severity of GVHD in hosts given bone mar-
row transplants stringently depleted of T cells (8, 9). In hu-
mans undergoing bone marrow transplantation, the major
potential sources of GVHD-inducing donor 
 
a
 
/
 
b
 
1
 
 T cells
come from the bone marrow itself or from the peripheral
blood that contaminates the bone marrow during its har-
vest (10–12). In humans, GVHD is severe even in MHC-
matched siblings with only minor histocompatibility anti-
gens mismatched, unless anti-GVHD prophylactic drugs are
used (1–4, 8, 9). In contrast, GVHD in mice after trans-
plantation of both MHC- and minor antigen–mismatched
bone marrow is usually mild, even when T cells are not de-
pleted and prophylactic drugs are not used (13–15). In most
murine GVHD models, 
 
a
 
/
 
b
 
1
 
 T cells from other tissue
sources, such as the spleen or lymph nodes, are added to
the bone marrow transplant for disease induction (16, 17).
This suggests either that bone marrow T cells may be in-
trinsically ineffective in causing GVHD in mice or that cel-
lular mechanisms may act to inhibit the GVHD-inducing
potential of bone marrow T cells.
The makeup of T cell subsets in the bone marrow differs
from that in the periphery, and the marrow T cells contain
an unusually high proportion of NK1.1
 
1
 
 T cells and CD4
 
2
 
CD8
 
2
 
 (double negative) T cells (18–21). NK1.1
 
1
 
 T cells
have been reported to ameliorate autoimmune diseases (22–
24), and CD4
 
2
 
CD8
 
2
 
 T cells have been reported to amelio-
rate GVHD (25–27). The object of the current report was
to study the abilities of purified NK1.1
 
2
 
, NK1.1
 
1
 
, and CD4
 
2
 
CD8
 
2
 
 T cells in the marrow to induce or regulate GVHD.
The experimental results showed that sorted NK1.1
 
2
 
 CD4
 
1
 
and CD8
 
1
 
 T cells from the blood or marrow induced acute
lethal GVHD, and NK1.1
 
1
 
 T cells suppressed GVHD, re-
gardless of whether they were found amongst the CD4
 
2
 
CD8
 
2
 
 or CD4
 
1
 
 and CD8
 
1
 
 T cells in the marrow. Almost
all CD4
 
2
 
CD8
 
2
 
 marrow T cells were NK1.1
 
1
 
, but only a
minority of CD4
 
1
 
 and CD8
 
1
 
 T cells were NK1.1
 
1
 
. The
suppressive activity of the NK1.1
 
1
 
 T cells was dependent 
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on their secretion of IL-4, as NK1.1
 
1
 
 T cells from IL-4
 
2
 
/
 
2
 
donor mice failed to ameliorate and even worsened GVHD
as compared to those from wild-type mice.
 
Materials and Methods
 
Mice and Monitoring of GVHD.
 
C57BL/6 (H-2
 
b
 
) wild-type,
C57BL/6 IL-4
 
2
 
/
 
2
 
, and BALB/c (H-2
 
d
 
) wild-type mice were ob-
tained from the Department of Comparative Medicine, Stanford
University breeding facility. C57BL/6 IL-4
 
2
 
/
 
2
 
 mice have been
described in detail previously (28, 29). Only male mice were used
at 8–12 wk of age. Care of all experimental animals was in accor-
dance with institutional guidelines. Host mice were given 800 cGy
whole body irradiation from a 250 kV x-ray source and injected
via the tail vein within 12 h. Survival and appearance of mice was
monitored daily, and body weight was measured weekly. Mean
body weights of surviving mice in each group were determined
at day 100. Chimerism in the peripheral blood of hosts at day 100
was measured by staining PBMC from Ficoll-hypaque gradients
with fluorochrome-conjugated anti–H-2
 
b
 
 mAbs (PharMingen) and
analysis by one-color flow cytometry.
 
Monoclonal Antibodies, Immunofluorescent Staining, and Flow Cyto-
metric Analysis.
 
Bone marrow cells were obtained from the femur
and tibia and stained with mAbs as described previously (21, 30).
Stainings were performed in the presence of anti-CD16/32
(2.4G2; PharMingen) at saturation to block FcRII/III receptors,
and propidium iodide (Sigma Chemical Co.) was added to staining
reagents to exclude dead cells. Three-color FACS
 
®
 
 analysis was
performed using a modified dual laser FACS Vantage™ (Becton
Dickinson), and data was analyzed using FACS
 
®
 
/Desk software
(Becton Dickinson; 21, 30). The following conjugated antibodies
were used for staining: FITC–anti-CD8 (CT-CD8
 
a
 
) purchased
from Caltag, Inc., and allophycocyanin–anti-TCR
 
ab
 
 (H57-597),
PE–anti-NK1.1 (PK136), and FITC–anti-CD4 (RM4-5) pur-
chased from PharMingen.
 
Sorting of Peripheral Blood and Bone Marrow T Cells.
 
PBMC or
marrow cells from wild-type C57BL/6 mice were stained with
anti-CD4, anti-CD8, and anti-TCR
 
ab
 
 mAbs and sorted CD4
 
1
 
and CD8
 
1
 
 
 
a
 
/
 
b
 
1
 
 T cells (CD4
 
1
 
/CD8
 
1
 
) from the blood or strin-
gently T cell–depleted (TCD)
 
1
 
 marrow cells (CD4
 
2
 
CD8
 
2
 
a
 
/
 
b
 
2
 
)
were obtained by flow cytometry using a FACStar™ (Becton
Dickinson) as described previously (21, 30). Sorted CD4
 
1
 
/CD8
 
1
 
T cells from the marrow were obtained by flow cytometry after
enrichment of bone marrow T cells on immunomagnetic bead
columns (Miltenyi Biotec). Marrow cells were first incubated
with biotinylated anti–Thy-1 mAb (Caltag, Inc.) and then incu-
bated with streptavidin magnetic beads. Thy-1
 
1
 
 cells were posi-
tively selected by retention on the magnetic columns and subse-
quent release.
 
In Vitro Secretion and Measurement of Cytokines.
 
Sorted T cells
(10
 
5
 
) from the peripheral blood or bone marrow from wild-type
or IL-4
 
2
 
/
 
2
 
 mice were stimulated in vitro with 20 ng/ml PMA
(Sigma Chemical Co.) and 1 
 
m
 
M Ionomycin (Calbiochem
Corp.) in 10% FBS and RPMI complete medium in 96-well
round-bottom plates and harvested at the peak time point (48 h)
as described previously (21). Supernatants were assayed for the se-
cretion of IFN-
 
g
 
 and IL-4 using commercial ELISA kits (Bio-
source International). Assays were developed with avidin-peroxi-
dase and substrate, and plates were read at 450 nm using a
microplate reader (21).
 
Histopathology of Skin and Large Intestine.
 
Histopathological
specimens from the skin and large intestines of hosts were ob-
tained 40–60 d after transplantation and fixed in formalin before
embedding in paraffin blocks. Tissue sections were stained with
hematoxylin and eosin and examined at 400
 
3
 
.
 
Results
 
Comparing Abilities of CD4
 
1
 
 and CD8
 
1
 
 T Cells from Blood or
Bone Marrow to Induce GVHD.
 
To test the ability of T cells
from murine peripheral blood to cause GVHD, we stained
PBMC from C57BL/6 mice and isolated CD4
 
1
 
 and CD8
 
1
 
T cells as a single pool by flow cytometry (hereafter referred
to as CD4
 
1
 
/CD8
 
1
 
 T cells). Graded numbers of these puri-
fied T cells were mixed with a constant number of unfrac-
tionated (1.5 
 
3
 
 10
 
6
 
) C57BL/6 bone marrow cells and in-
jected intravenously into lethally irradiated BALB/c mice.
Injection of complete H-2–mismatched unfractionated
bone marrow from C57BL/6 mice into lethally irradiated
BALB/c mice allowed 100% of mice to survive for at least
100 d (Fig. 1 A). Control irradiated hosts given no donor
cells all died by day 14, whereas those reconstituted with
the unfractionated bone marrow cells alone were complete
chimeras with donor-origin (H-2
 
b
 
) blood mononuclear
cells at day 100, based on staining for surface H-2
 
b
 
 expres-
sion and flow cytometric analysis (data not shown). The ad-
dition of graded numbers of purified CD4
 
1/CD81 peripheral
blood T cells to the transplant resulted in dose-dependent
mortality, with the addition of as few as 1.6 3 104 of these
cells causing a significant decrease (P , 0.05 by the log
rank test) in survival compared to transplantation of unfrac-
tionated bone marrow alone (Fig. 1 A).
Because  z2% of nucleated bone marrow cells were
brightly staining a/b1 T cells (Fig. 2 E), we next determined
whether stringent depletion of T cells (Fig. 2 E, left box)
prior to transplant would further decrease the mortality from
the addition of peripheral blood CD41/CD81 T cells. Sur-
prisingly, T cell depletion of the bone marrow actually
increased rather than decreased mortality compared to trans-
plantation with unfractionated bone marrow, and this ef-
fect was observed over a large range of doses of peripheral
blood CD41/CD81 T cells (Fig. 1 B). Strikingly, the addition
of as few as 8 3 103 CD41/CD81 T cells from the periph-
eral blood to TCD bone marrow cells resulted in signifi-
cantly decreased host survival as compared to either trans-
plantation of TCD bone marrow cells alone or to hosts given
8 3 103 CD41/CD81 blood T cells plus unfractionated
bone marrow cells (Fig. 1, A and B; P , 0.01 and 0.001,
respectively). Only z30% of the hosts given the combina-
tion with TCD marrow cells survived more than 100 d,
and those that died showed typical signs of GVHD includ-
ing weight loss, hunched back, ruffled fur, diarrhea, and
facial swelling. Necropsies of moribund hosts with severe
clinical signs after day 40 showed typical GVHD histo-
pathological lesions of the large intestines and skin (see be-
low). Increasing the dose of CD41/CD81 peripheral blood
T cells accelerated the rapidity of death of the hosts until
a plateau was reached between 6.4 3 104 and 2.56 3 105 1Abbreviation used in this paper: TCD, T cell–depleted.1075 Zeng et al.
T cells. Hosts given the latter cell doses all died by day 14
after cell transplantation (Fig. 1 B).
To test the notion that a/b1 T cells in the bone marrow
were responsible for protection from GVHD, these cells
were purified from the bone marrow (Fig. 2 E) and added
back to the TCD bone marrow with 6.4 3 104 peripheral
blood CD41/CD81 T cells, a dose that resulted in 100%
mortality by day 14 posttransplantation (Fig. 1 B). Under
these conditions, the inclusion of 2.56 3 105 a/b1 T cells
significantly delayed mortality (P , 0.05), and the inclu-
sion of 1.024 3 106 of these cells resulted in the long-term
survival of 50% of the transplant recipients (Fig. 1 C). This
inhibitory effect on GVHD was specific for a/b1 T cells of
the bone marrow, in that the addition of 1.024 3 106 TCD
bone marrow cells provided no protection from mortality
(Fig. 1 C).
Because bone marrow a/b1 T cells enriched on immu-
nomagnetic bead columns include populations that express
CD4 or CD8 markers or neither marker (CD42CD82;
Fig. 2 C), we next directly assessed the capacity of purified
CD41/CD81 a/b1 T cells from the enriched bone marrow
to mediate GVHD. When these were added at a ratio of
1.28 3 105 or 2.56 3 105 donor T cells/1.5 3 106 TCD
marrow cells, 100 and 90% of the hosts, respectively, sur-
vived for more than 100 d (Fig. 1 D). The surviving hosts
did not show signs of GVHD, and their mean body weight
at day 100 posttransplantation did not differ significantly
from that of mice that had received TCD bone marrow
Figure 1. Ability of peripheral blood (PB) and bone marrow (BM)
CD41 and CD81 T cells to induce lethal GVHD. Graded numbers of
sorted CD41/CD81 T cells were added to a constant number (1.5 3 106)
of unfractionated or TCD C57BL/6 marrow cells and injected intra-
venously into lethally irradiated (800 cGy) BALB/c hosts. Survival over a
100-d observation period is shown in groups of 10 mice. (A) Graded
numbers of sorted peripheral blood CD41/CD81 T cells were added to
unfractionated marrow cells. (B) Graded number of sorted peripheral
blood CD41/CD81 T cells were added to TCD marrow cells. (C) 6.4 3
104 peripheral blood CD41/CD81 T cells and 1.5 3 106 TCD marrow
cells were or were not injected with sorted TCRa/b1 marrow T cells or
with TCD marrow cells. (D) Sorted CD41/CD81 T cells from the mar-
row were injected with 1.5 3 106 TCD marrow cells.
Figure 2. Two-color flow cytometric analysis of a/b1 T cells in the
peripheral blood, bone marrow, and T cell–enriched bone marrow of
C57BL/6 wild-type or C57BL IL-42/2 mice. A and B show staining of
wild-type PBMC. (A) CD4 and CD8 (using same fluorochrome) versus
TCRab markers; the two boxes enclose CD41/CD81 (upper) and
CD42CD82 (lower) TCRabhi cells. (B) Analysis of the gated TCRabhi
cells for CD4 and CD8 versus NK1.1. Left upper box encloses NK1.12
CD41/CD81 cells, right upper box encloses NK1.11 CD41/CD81 cells,
and right lower box encloses NK1.11 CD42CD82 cells. C and D show
similar analyses for immunomagnetic bead–enriched wild-type bone
marrow T cells. F and G show analyses of enriched IL-42/2 bone marrow
T cells. E shows analysis of whole wild-type bone marrow cells before
enrichment of T cells and thresholds for gating TCD bone marrow cells
(E, left box). Sorted TCRab1 bone marrow cells were all cells to the
right of the TCRab gating threshold. H shows analysis of whole bone
marrow cells before enrichment from IL-42/2 mice. K shows analysis of
enriched bone marrow cells from wild-type mice; box encloses TCRabhi
cells. I and J show the analyses of the gated TCRabhi cells for CD8 or
CD4 versus NK1.1, respectively. Percentages of cell subsets enclosed in
boxes are shown.1076 NK1.11 T Cells Regulate GVHD
alone (data not shown). Bone marrow CD41/CD81 T
cells were therefore strikingly ineffective in inducing lethal
GVHD. In control experiments, PBMC were applied to
immunomagnetic bead columns, and sorted CD41/CD81
T cells were obtained thereafter by flow cytometry. These
T cells (3.2 or 6.4 3 104) were injected with TCD marrow
cells into groups of 10 BALB/c hosts, and survival was
compared to that of hosts given the same number of sorted
peripheral blood CD41/CD81 T cells without column en-
richment. The column-enriched cells remained as effective
as an equivalent number of these T cells obtained without
column enrichment in mediating lethal GVHD (data not
shown).
NK1.11 T Cells Regulate GVHD. Previous studies have
shown that bone marrow a/b1 T cells from C57BL/6 mice,
as well as several other strains, have a substantially greater
proportion of cells with surface expression of NK1.1 than
peripheral blood a/b1 T cells (18, 21). As there is recent
evidence that NK1.11 a/b1 T cells may act as negative
regulators of T cell–dependent autoimmune diseases (22–
24), it was plausible that a bone marrow NK1.11 T cell
population might act in a similar negative regulatory fash-
ion in GVHD. Therefore, we analyzed bone marrow and
peripheral blood a/b1 T cells for their surface expression
of CD4 plus CD8 versus NK1.1. This revealed that z30%
of C57BL/6 PBMC were a/b1 T cells that expressed ei-
ther CD4 or CD8 (Fig. 2 A). CD4 and CD8 are expressed
in a mutually exclusive pattern (21). Less than 1% of the
peripheral blood a/b1 T cells expressed NK1.1 (Fig. 2 B),
in agreement with previous reports (19, 20). In contrast,
z20% of bone marrow a/b1 T cells were CD42CD82
(Fig. 2 C, lower box), and most of the CD42CD82 T cells
were NK1.11 (Fig. 2 D, lower box). 16% of bone marrow
a/b1 T cells were NK1.11 and either CD41 and/or CD81
(upper box). Further analysis of gated a/b1 T cells from
the bone marrow (Fig. 2 K) showed that the percentage
of NK1.11CD81 T cells exceeded that of NK1.11CD41
T cells (Fig. 2, compare I and J). Although NK1.11CD81
T cells were easily identified in the bone marrow, this sub-
set was not detected in the peripheral blood, thymi, or
spleens of the donor mice (data not shown).
Because the CD41/CD81 T cell subset of bone marrow
cells contained a substantial proportion of NK1.11 cells
but the peripheral blood did not, we tested the ability of
purified CD41/CD81 T cells depleted of NK1.11 T cells
to induce GVHD. As before, the addition of 2.00 3 105
CD41/CD81 T cells (including the NK1.11 population)
to the TCD bone marrow transplant induced minimal clini-
cal signs of GVHD in irradiated BALB/c hosts, and no deaths
occurred during a 100-d observation period (Fig. 3 A). In
contrast, an equal number of NK1.1-depleted CD41/
CD81 T cells added to TCD bone marrow resulted in the
death of z70% of hosts within 20 d and was associated
with clinical signs of GVHD including facial swelling, hair
loss, hunched back, and weight loss (Fig. 3 A). Reduction
of the NK1.1-depleted CD41/CD81 T cell dose to 1.00 3
105 cells still resulted in the death of z40% of hosts by day
20. This was a significant reduction in survival (P , 0.01,
log rank test) as compared to the group given sorted CD41/
CD81 T cells. Histopathological examination of the large in-
testines and skin of additional mice given 2.00 3 105 NK1.12
T cells showed lesions of GVHD, including inflammation
in the intestinal crypts and hyperplasia and apoptosis of crypt
epithelial cells, inflammation of the dermis, and epidermal
hyperplasia as compared to mice given TCD bone marrow
alone (Fig. 4, A–D).
Regulation of GVHD by NK1.11 T Cells is IL-4 Depen-
dent. Unlike conventional a/b1 T cells, NK1.11 T-lineage
cells of the thymus and spleen rapidly secrete large amounts
of IL-4 and IFN-g after engagement of the TCR–CD3
complex or after stimulation with calcium ionophore and
phorbol PMA, without previous exposure to antigens or
polyclonal T cell activators (31–33). IFN-g and IL-4 are
important in helping to polarize T cell responses toward
Th-1 or Th-2 patterns of cytokine production that have been
implicated in the induction and amelioration of GVHD, re-
spectively (34–36). Therefore, we characterized the capac-
Figure 3. Different subsets of T cells induce or suppress GVHD, de-
pending on their cytokine secretion profiles. (A) Sorted C57BL/6 wild-
type CD41 and CD81 bone marrow (BM) T cells with or without deple-
tion of NK1.11 T cells were added to C57BL/6 wild-type TCD bone
marrow cells (1.5 3 106) and injected into irradiated BALB/c hosts. In
addition, sorted C57BL IL-42/2 CD41 and CD81 bone marrow T cells
without NK1.11 T cell depletion were added to wild-type TCD bone
marrow cells and injected into BALB/c hosts. (B) Sorted CD42CD82
T cells from the bone marrow of wild-type or IL-42/2 C57BL/6 donor
mice were added to 2.00 3 105 sorted wild-type NK1.12 CD41/CD81
bone marrow T cells and 1.5 3 106 wild-type TCD bone marrow cells.
Control mice received sorted wild-type NK1.12 CD41/CD81 bone
marrow T cells and TCD bone marrow cells without added-back
CD42CD81 bone marrow T cells (none). There were 10 mice in each
group.1077 Zeng et al.
ity of bone marrow T cells, including the NK1.11 popula-
tion, to produce these cytokines after in vitro stimulation
with calcium ionophore and PMA for 48 h, a time point
at which cytokine levels were maximal (21). Depletion of
NK1.11 T cells from the bone marrow CD41/CD81 T cell
population resulted in an eightfold reduction of IL-4 pro-
duction (Table I) that was highly significant (P , 0.01, two-
tailed Student’s t test). In contrast, secretion of IFN-g was
similar in unfractionated versus NK1.1-depleted bone mar-
row CD41/CD81 T cells. In comparison, sorted peripheral
blood CD41/CD81 T cells secreted high levels of IFN-g
and a low level of IL-4 (Table I). Therefore, a high ratio of
IFN-g/IL-4 production correlated with the capacity to in-
duce severe GVHD.
To determine whether the high capacity of NK1.11
bone marrow T cells to produce IL-4 was important for
the negative regulation of GVHD by this cell population,
bone marrow CD41/CD81 T cells from wild-type and
IL-42/2 mice of the C57BL/6 background were used to
induce GVHD in the irradiated BALB/c hosts. The surface
phenotype and percentages of bone marrow a/b1 T cells,
particularly the NK1.11 and CD42CD82 T cell subsets, were
similar in IL-42/2 (Fig. 2, F–H) and wild-type mice (Fig. 2,
C–E), indicating that IL-4 is not required for NK1.11 T cell
Figure 4. Different subsets of
NK1.12 and NK1.11 T cells in-
duce or suppress histopathological
lesions of GVHD in the large in-
testine and skin. Sections of intes-
tine (A) and skin (B) from irradi-
ated BALB/c hosts injected 60 d
earlier with only TCD bone mar-
row from wild-type C57BL/6 do-
nor mice. Plump, mucin-contain-
ing epithelial cells are seen in the
intestine (arrows) with little or no
inflammation. C and D show
BALB/c hosts injected with wild-
type TCD bone marrow and
sorted wild-type NK1.12 CD41/
CD81 bone marrow T cells. An
inflammatory infiltrate between
intestinal crypts and hyperplasia
of crypt epithelial cells with
reduced mucin characteristic of
GVHD is seen (arrow). An in-
flammatory infiltrate in the dermis
and epidermal hyperplasia charac-
teristic of GVHD is observed in
the skin (arrows). E and F show
hosts injected with wild-type
TCD bone marrow, sorted wild-
type NK1.12 CD41/CD81 bone
marrow T cells, and sorted wild-
type CD42CD82 (NK1.11) bone
marrow T cells. Lesions of GVHD
are markedly reduced. G and H
show hosts injected with wild-
type TCD bone marrow, sorted
wild-type NK1.12 CD41/CD81
bone marrow T cells, and sorted
IL-42/2 CD42CD82 (NK1.11)
bone marrow T cells. Severe le-
sions of GVHD are seen, includ-
ing an abscess in an intestinal
crypt (arrow).1078 NK1.11 T Cells Regulate GVHD
development. The percentage of CD41 and CD81 NK1.11
T cells in the IL-42/2 mice was also similar to that in the
wild type (data not shown). Whereas 2.00 3 105 of wild-
type CD41/CD81 bone marrow T cells failed to induce le-
thal GVHD (Fig. 3 A), the addition of 1.00 3 105 of these
bone marrow T cells from IL-42/2 mice to the transplant
induced lethal GVHD in 90% of irradiated BALB/c hosts
by day 11 (Fig. 3 A). Reduction of the dose of IL-42/2
CD41/CD81 T cells to 5.0 and 2.5 3 104 resulted in the
reduction of lethal GVHD to 60 and 50%, respectively (Fig.
3 A). Examination of surviving hosts at day 40 again
showed histopathological evidence of GVHD of the large
intestine (data not shown). Purified CD41 and CD81 bone
marrow T cells from IL-42/2 donors secreted no detectable
IL-4, and high levels of IFN-g that were not significantly
different than that of cells from wild-type C57BL/6 mice
(Table I). Taken together, these results indicate that the
NK1.11 subset of CD41/CD81 bone marrow T cells in-
hibited the induction of GVHD by NK1.12 subset and that
this inhibition was IL-4 dependent.
We attempted to directly test the suppressive capacity of
purified NK1.11 CD41/CD81 T cells on GVHD. How-
ever, as immunofluorescent staining of bone marrow T cells
with anti-NK1.1 mAb, a step required for cell purification
by positive selection, substantially reduced the capacity of
CD41/CD81 T cells to secrete IL-4 in vitro (Table I), this
approach was not pursued. As an alternative approach, we
performed experiments in which purified CD42CD82 a/b1
T cells from the bone marrow, which are almost all NK1.11
(Fig. 2 D), were combined with NK1.12 CD41/CD81
bone marrow T cells and transplanted with TCD bone
marrow. These purified bone marrow CD42CD82 a/b1
T cells secreted levels of IL-4 (mean 829 pg/ml) and IFN-g
(mean 1,216 pg/ml) that lacked a statistically significant dif-
ference (P . 0.1) from that of NK1.11-containing bone
marrow CD41/CD81 T cells (Table I). Addition of 1.00 3
105 CD42CD82 bone marrow T cells and 2.00 3 105
NK1.12 CD41/CD81 bone marrow T cells to the trans-
plant significantly increased the survival of the irradiated
hosts (P , 0.01, log rank test) as compared to the injection
of only NK1.12 CD41/CD81 bone marrow T cells and
TCD bone marrow (Fig. 3 B). Only 10% of host mice died
by day 60 in the group that received CD42CD82 T cells. In
contrast, the addition of 1.00 3 105 sorted CD42CD82
bone marrow T cells from IL-42/2 mice resulted in re-
duced survival, and 80% of hosts died by day 12 posttrans-
plantation. Surviving hosts given CD42CD82 bone marrow
T cells from wild-type or IL-42/2 donors were killed on
day 60. Interestingly, the large intestines and skin of hosts
given IL-42/2 CD42CD82 T cells showed more severe
histopathological lesions of GVHD compared not only to
recipients of wild-type CD42CD82 T cells but also to
hosts that received only NK1.12 CD41/CD81 T cells with
TCD bone marrow (Fig. 4, E–H). The sorted CD42CD82
bone marrow T cells from the IL-42/2 donors secreted a
high level of IFN-g (mean 1,024 pg/ml) that was similar to
the level secreted by CD42CD82 bone marrow T cells
(Table I). This indicates that the secretion of IFN-g by
NK1.11 T cells, when it is unopposed by IL-4 secretion,
exacerbates rather than inhibits GVHD.
Discussion
We directly compared the ability of sorted CD4 and
CD8 T cells obtained from the peripheral blood or bone
marrow of C57BL/6 mice to induce acute GVHD in le-
thally irradiated BALB/c hosts coinjected with stringently
TCD C57BL/6 marrow cells. The peripheral blood T cells
were at least 30-fold more potent than the marrow T cells
on a per-cell basis as judged by mortality of the hosts dur-
ing a 100-d observation period. In fact, no significant mor-
tality was induced by the sorted marrow T cells in the dose
range tested unless the NK1.11 T cells were removed or
the sorted marrow T cells were obtained from IL-42/2 do-
Table I. Cytokine Production by Bone Marrow (BM) and Peripheral Blood (PB) T Cells
Cells (1.00 3 105) IL-4* IFN-g* IFN-g/IL-4 ratio
pg/ml pg/ml
PB CD41/CD81 T (wt, n 5 6) 18 6 4 566 6 75 32
BM CD41/CD81 T (wt, n 5 6) 528 6 67 1,216 6 108 2.3
BM CD41/CD81 T NK1.12 (wt, n 5 6) 73 6 13 992 6 52 14
BM CD41/CD81 T (IL-42/2, n 5 6) 0 6 0 1,657 6 267 —
BM CD42/CD82 T (wt, n 5 6) 829 6 58 1,492 6 100 1.8
BM CD42/CD82 T (IL-42/2, n 5 4) 0 6 0 1,024 6 56 —
BM CD41/CD81 T (wt, anti-NK1.1, n 5 4) 281 6 19 1,419 6 28 5
BM CD42/CD82 T (wt, anti-NK1.1, n 5 4) 247 6 8 1,305 6 114 5.3
*Values are the means 6 SE of replicate experiments from individual donor mice. In some experiments, BM cells were stained with anti-NK1.1
monoclonal antibodies as well as with the anti-CD4, anti-CD8, and anti-TCRab antibodies used for sorting. Cytokine patterns of sorted cells in
which anti-NK1.1 antibodies were included in the staining mixture are also shown (anti-NK1.1). wt, wild type.1079 Zeng et al.
nors. Surprisingly, the bone marrow NK1.11 T cells con-
tained CD41, CD81, and CD42CD82 subsets, whereas
only the CD41 and CD42CD82 subsets could be detected
in the thymus and spleen as reported previously (20). CD41
and CD81 NK1.11 T cells in the marrow show similar cy-
tokine secretion profiles (Zeng, D., and S. Strober, manu-
script in preparation). Sorted wild-type NK1.11 T cells
(CD42CD82) from the marrow that secreted high levels of
both IFN-g and IL-4 suppressed GVHD as judged by mor-
tality and by histopathological changes in the skin and large
intestines. In contrast, sorted IL-42/2 NK1.11 T cells that
secreted high levels of IFN-g without IL-4 exacerbated
mortality and the histopathological changes of GVHD.
The experimental results show that peripheral blood or
bone marrow NK1.12 a/b1 T cells induce and NK1.11
a/b1 T cells potently suppress acute lethal GVHD and that
this negative regulatory effect requires IL-4. These results
agree with and extend previous studies showing that CD42
CD82 T cells (“natural suppressor” cells) inhibit GVHD
(25–27), and CD41 or CD81 T cells that secrete a Th1-type
cytokine pattern (e.g., IFN-g and IL-2, but not IL-4) induce
GVHD and those that secrete a Th2-type pattern (e.g., IL-4,
but not IFN-g and IL-2) are protective (34–36). However,
two recent studies concluded that secretion of IFN-g by allo-
geneic donor cells is not required for the induction of lethal
GVHD in irradiated hosts, as donor cells from IFN-g2/2
mice induced lethal disease in either wild-type or IFN-g2/2
hosts (37, 38). In some studies, injection of IFN-g or IL-12
into allogeneic bone marrow transplant hosts protected against
GVHD when given at the same time or shortly after the
injection of the donor cells (39, 40). The current study did
not determine whether the induction of GVHD was de-
pendent upon IFN-g secretion by donor NK1.12 T cells,
and it is possible that alloantigen-induced secretion of other
cytokines such as IL-2 is critical for the development of the
disease (37). The current results suggest that NK1.11 T cell
secretion of IFN-g in the absence of IL-4 can worsen GVHD
when it is induced by donor NK1.12 T cells, perhaps due
to the specific kinetics and localization of IFN-g secretion
by the NK1.11 T cells.
GVHD induced by donor spleen cells added to TCD
donor bone marrow cells has been reported to be less vig-
orous when IL-42/2 rather than wild-type donor mice are
used (37). The latter result appears contradictory to the in-
crease in severity of GVHD induced by bone marrow CD41/
CD81 T cells from IL-42/2 donors as compared to wild-
type donors in the current study. Because the percentage of
NK1.11 T cells in the spleen is quite low and comparable
to that in the peripheral blood, changes in the ability of
splenic T cells from wild-type versus cytokine-deficient do-
nors to induce GVHD are likely to reflect changes mainly in
the function of NK1.12 T cells, which recognize predomi-
nantly polymorphic MHC class I and II antigens. How-
ever, changes in the ability of bone marrow T cells from
IL-42/2 donor mice to induce GVHD are due mainly to
changes in the function of NK1.11 T cells, which recog-
nize the nonpolymorphic CD1 antigen (20). A simple Th1/
Th2 paradigm cannot explain the capacity of all T cell sub-
sets to induce or protect against GVHD in a variety of
animal models of bone marrow transplantation, as a given
cytokine such as IFN-g can ameliorate or worsen disease
depending on the preparatory regimen (lethal versus sub-
lethal or no irradiation) used to treat the host (37, 41).
Decreased production of NK1.11 a/b thymocytes and a
resulting decrease in NK1.11 a/b T-lineage cell–mediated
IL-4 production appears to play a key role in the develop-
ment of diabetes mellitus in nonobese diabetic mice, a dis-
ease which depends on NK1.12 a/b1 T cells for its devel-
opment (22–24). Taken together with our observations, this
suggests that the NK1.11 a/b1 T cell population is an im-
portant negative regulator of other a/b1 T cell populations.
A human CD42CD82 a/b1 T cell subset (Va24-JaQ) is
found in most healthy individuals and has striking similari-
ties to the murine NK1.11 a/b1 T cell population (42, 43).
These similarities include a highly limited ab-TCR reper-
toire that is restricted, at least in part, by the CD1d mole-
cule (43). In addition, this subset expresses high levels of
NKR-P1A, the human homologue of murine NK1.1 mol-
ecule, and has a high capacity to produce IL-4 and IFN-g
(43). Therefore, given our results, it will be of interest to
determine if inclusion rather than depletion of donor
Va24-JaQ CD42CD82 T cells in allogeneic bone marrow
transplantation reduces GVHD in humans. Our results also
raise the possibility that IL-4 produced by this CD42CD82
T cell population or administered therapeutically might
prevent or ameliorate GVHD in humans.
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